Vocalbeats.AI Achieves ISO/IEC 42001 Certification, Reinforcing Responsible AI Governance Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July…
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Wednesday, July 12th at 11:00 AM ET OCALA, Fla., July…
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Wednesday, July 12th at 11:00 AM ET OCALA, Fla., July…
Sofwave™ Gains Additional U.S. Patent Protection For the Company’s Proprietary SUPERB™ Technology
• The patent protects additional feature sets of SUPERB’s ultrasound and cooling technology • New patent…
Sofwave™ Gains Additional U.S. Patent Protection For the Company’s Proprietary SUPERB™ Technology
• The patent protects additional feature sets of SUPERB’s ultrasound and cooling technology • New patent…
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Talis Biomedical Announces 1-for-15 Reverse Stock Split
REDWOOD CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Talis Biomedical Announces 1-for-15 Reverse Stock Split
REDWOOD CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on…
Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder
Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on…
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE…
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE…
Spectral Medical Announces the Opening of Three Additional Tigris Clinical Trial Sites
University of Alabama enrolls patient 65 after second day of opening for enrollment TORONTO, July…
Spectral Medical Announces the Opening of Three Additional Tigris Clinical Trial Sites
University of Alabama enrolls patient 65 after second day of opening for enrollment TORONTO, July…
Cognition Therapeutics and the Alzheimer’s Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that…
Cognition Therapeutics and the Alzheimer’s Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that…
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
LONDON, July 05, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company…